BUY Mankind Pharma Limited — Shrikant Chouhan, Kotak Securities
byShrikant Chouhan, Kotak SecuritiesHorizon: 1–3 months29 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
MACD above its signal line — bullish momentum
Technicals · macd·30 Sept · today
4 other SEBI-registered advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · same horizon·30 Sept · today
8 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · adjacent horizon·24 Sept · 6d ago
Mankind Pharma shares up 10% in just 4 sessions; Kotak upgrades the stock - Target, share price trend
NewsLivemint·22 Sept · 1w ago
Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the street
NewsCnbc-Tv18·22 Sept · 1w ago
Mankind Pharma Gets 68.21 ESG Rating From Niche99 In Leader Category
NewsGoogle News·16 Sept · 2w ago
Mankind Pharma to attend three investor conferences in September 2026
NewsGoogle News·11 Sept · 3w ago
Mankind Pharma to meet investors in Mumbai on June 1-2
NewsGoogle News·11 Sept · 3w ago
Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation
NewsGoogle News·28 Sept · 2d ago
Mankind Pharma's subsidiary Bharat Serums and Vaccines sees auditor resignation amid liquidation
NewsGoogle News·28 Sept · 2d ago
1 advisor has an active long-term SELL call on this stock
Advisor consensus · adjacent horizon·31 Jul · 2mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.